Position: 51 shares @ $25.84 | Current: ~$28.23 (+9.2%) | Conviction: 5/10 --- 1. IS MY ORIGINAL THESIS STILL INTACT? Short answer: The macro narrative survives, but the trade mechanics are broken. My original thesis — placed May 11, escalated April 14 — rested on a single catalyst: Iran supply shock → oil sustainably higher → CVE's consolidated production assets benefit from stronger realizations and expanding refining margins. The underlying data still holds: - CVE's Q4 2025 assets hit $63.4B (vs. $56.5B in Dec 2024) — the balance sheet is absorbing strategic positioning - Revenue remained elevated at $49.7B in Q4 2025 (vs. $54.3B full-year 2024) — still run-rate strong But the real-world catalyst has rotted from underneath: | Event | Date | My Thesis Impact | Reality Check | |-------|------|------------------|----------------| | Iran escalation thesis originated | May 11 | Bullish: Hormuz risk = oil premium | Geopolitical risk priced as permanent | | Iran conflict "went live" | Jun 01 | Should be bullish: Supply shock catalyst | Oil spiked briefly; no structural shortage materialized | | OPEC+ approves 4th output hike since Hormuz closure | Jun 07 | Bearish to thesis: Supply surge counters shortage narrative | This is the problem | Today's news is the thesis-killer: OPEC+ just approved its FOURTH oil output quota increase since the Hormuz closure. What that means in plain terms: - OPEC is deliberately flooding the market to keep prices moderate - The "Hormuz premium" that justified my entry is being systematically drained by quota expansion - Supply is being weaponized against the exact

Research these companies